@article{wolf_ruterbories_handel_hansen_2024, title={The effect of ε-aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs}, ISSN={["1939-1676"]}, DOI={10.1111/jvim.16977}, abstractNote={AbstractBackgroundNo treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs.ObjectivesPrimary: determine if treatment with ε‐aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs with severe thrombocytopenia. Secondary: find evidence of hyperfibrinolysis and determine the effect EACA administration on rapid (rTEG) and tissue plasminogen activator‐spiked (tPA‐rTEG) thromboelastography parameters.AnimalsTwenty‐seven dogs with severe thrombocytopenia were treated with EACA, and data from an additional 33 were obtained from the hospital database as historical control (HC) cohort.MethodsSingle arm clinical trial with HCs. The EACA group dogs received EACA (100 mg/kg IV followed by a constant‐rate infusion [CRI] of 400 mg/kg/24 hours). Thromboelastography before and during EACA infusion, hospitalization days, number of transfusions, and mortality were compared.ResultsNo difference was found in number of transfusions per dog (median, interquartile range; 1, 0‐2.5 vs 0.9, 0‐2; P = .5) and hospitalization days (4, 4‐6 vs 4.5, 3.75‐6; P = .83) between HC and EACA groups, respectively, and no difference in survival was identified by log‐rank analysis (P = .15). Maximum amplitude on both rTEG and tPA‐rTEG increased after EACA administration (rTEG baseline: 23.6, 9.6‐38.9; post‐EACA: 27.3, 19.8‐43.2; P < .001; tPA‐rTEG baseline: 23, 10.9‐37.2; post‐EACA: 24.7, 16.7‐44.8; P < .002).Conclusions and Clinical ImportanceAlthough EACA increased clot strength, there was no effect on outcome. Treatment with EACA at this dosage cannot be recommended as a routine treatment but may be considered for dogs with severe ongoing hemorrhage.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Wolf, Johanna and Ruterbories, Laura K. and Handel, Ian and Hansen, Bernie}, year={2024}, month={Jan} }
 @article{rank_lynch_ruterbories_li_ueda_2023, title={Evaluation of thrombin generation in dogs administered clopidogrel}, volume={10}, ISSN={2297-1769}, url={http://dx.doi.org/10.3389/fvets.2023.1194242}, DOI={10.3389/fvets.2023.1194242}, abstractNote={IntroductionThe antiplatelet effect of clopidogrel can vary between patients. A modified thromboelastography (TEG) protocol (TEG-Platelet Mapping assay® [TEG-PM]) can be used for clopidogrel monitoring but is not widely available. Thrombin generation (TG) assays could offer a novel alternative. The main objective of this pilot study was to assess TG assay variables (lag time, peak, endogenous thrombin potential [ETP]) in dogs before and after 7 days of clopidogrel administration and compare with TEG-PM variables (maximum amplitude [MA]-ADP and percentage (%) inhibition).MethodsSix healthy mix-breed dogs were enrolled in this pilot study. Blood samples for platelet count, TG assays, and TEG-PM were obtained at two time points, corresponding to baseline, and after 7 days of clopidogrel administration (mean 2.3 +/− 0.3 mg/kg PO q24 hours). Data were then compared with a Student’s t-test.ResultsThere was no significant change in TG assay variables performed on platelet poor plasma after 7 days of clopidogrel administration: lag time (Day 1: 1.8 +/− 0.2 min, Day 7: 1.8 +/− 0.2 min, p = 0.42); peak (Day 1: 76 +/− 7 nM, Day 7: 72 +/− 10 nM, p = 0.49); and ETP (Day 1: 399 +/− 27 nM*min, Day 7: 392 +/− 32 nM*min; p = 0.49). There were significant changes in TEG MA-ADP (Day 1: 19 +/− 8 mm, Day 7: 9 +/− 6 mm, p = 0.04) and % inhibition (Day 1: 58 +/− 27, Day 7: 99 +/− 0.3, p = 0.02).DiscussionClopidogrel administration did not lead to changes in TG assay variables performed on platelet poor plasma samples, despite concomitant changes in TEG-PM variables consistent with platelet inhibition. Based on this pilot study, thrombin generation performed on platelet poor plasma may not be a useful antiplatelet monitoring tool in dogs.}, journal={Frontiers in Veterinary Science}, publisher={Frontiers Media SA}, author={Rank, Kaitlyn and Lynch, Alex M. and Ruterbories, Laura K. and Li, Ronald H. L. and Ueda, Yu}, year={2023}, month={Aug} }
 @article{lynch_ruterbories_robertson_lunn_mowat_2023, title={Hemostatic profiles in dogs with sudden acquired retinal degeneration syndrome}, volume={4}, ISSN={["1939-1676"]}, url={https://doi.org/10.1111/jvim.16710}, DOI={10.1111/jvim.16710}, abstractNote={AbstractBackgroundSudden acquired retinal degeneration syndrome (SARDS) is a common cause of irreversible blindness in dogs. It bears clinical resemblance to hypercortisolism, which can be associated with hypercoagulability. The role of hypercoagulability in dogs with SARDS is unknown.ObjectiveDetermine hemostatic profiles in dogs with SARDS.AnimalsProspective pilot study: Dogs with a history of SARDS (n = 12). Prospective case‐control study: Dogs with recent onset of SARDS (n = 7) and age‐, breed‐, and sex‐matched controls (n = 7).MethodsProspective pilot study: We performed thromboelastography (TEG). Prospective case‐control study: Dogs had CBC, serum biochemistry, urinalysis, TEG, fibrinogen concentration, antithrombin activity, D‐dimers, thrombin‐antithrombin complexes, and optical platelet aggregometry performed.ResultsProspective pilot study: 9/12 dogs with a history of SARDS were hypercoagulable with increased TEG G value and 2/3 had hyperfibrinogenemia. Case‐control study: All dogs with SARDS and 5/7 controls were hypercoagulable based on TEG G value. Dogs with SARDS had significantly higher G values (median, 12.7 kdynes/s; range, 11.2‐25.4; P = .04) and plasma fibrinogen concentration (median, 463 mg/dL; range, 391‐680; P < .001) compared to controls.Conclusions and Clinical ImportanceHypercoagulability was common in both dogs with SARDS and controls, but dogs with SARDS were significantly more hypercoagulable on TEG. The role of hypercoagulability in the pathogenesis of SARDS remains to be determined.}, number={3}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Lynch, Alex M. M. and Ruterbories, Laura K. K. and Robertson, James B. B. and Lunn, Katharine F. F. and Mowat, Freya M. M.}, year={2023}, month={Apr} }
 @article{kielb basile_lynch_ruterbories_castaneda_griffith_ueda_2021, title={Influence of long-stay jugular catheters on hemostatic variables in healthy dogs}, volume={7}, ISSN={["1476-4431"]}, url={https://doi.org/10.1111/vec.13085}, DOI={10.1111/vec.13085}, abstractNote={AbstractObjectiveTo compare hemostatic variables performed on blood samples obtained from indwelling jugular catheters or direct venipuncture over a 72‐hour period.DesignProspective experimental study.SettingUniversity research laboratory.AnimalsFive healthy neutered male purpose‐bred Beagle dogs.InterventionsEach dog was sedated to facilitate placement of a long‐stay 20‐Ga polyurethane IV catheter into the jugular vein. Blood samples were obtained from the preplaced catheters at 4 time points corresponding to 0, 24, 48, and 72 hours relative to placement. Blood samples were also obtained by direct venipuncture of a peripheral vein using a 21‐Ga butterfly catheter and evacuated blood tubes at the same time points. Platelet count, platelet closure time, prothrombin time, activated partial thromboplastin time, fibrinogen, and kaolin‐activated thromboelastography were performed on these paired samples at each time point. The patency of the indwelling catheters was maintained by flushing every 6 hours with heparinized saline.Measurements and Main ResultsNo significant differences were identified in any of the hemostatic variables obtained by either blood collection technique at any time point during the study (P > 0.05). There was also no significant day‐to‐day variation in any catheter‐derived hemostatic variable obtained from individual dogs identified over the course of the study.ConclusionsThese data suggest that accurate hemostatic variables may be obtained using blood collected from indwelling jugular catheters, maintained with heparinized saline for at least 72 hours, in healthy dogs.}, number={5}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Kielb Basile, Jessica L. and Lynch, Alex M. and Ruterbories, Laura and Castaneda, Kady and Griffith, Emily and Ueda, Yu}, year={2021}, month={Jul} }
 @article{harms_ruterbories_stacy_christiansen_papich_lynch_barratclough_serrano_2021, title={SAFETY OF MULTIPLE-DOSE INTRAMUSCULAR KETOPROFEN TREATMENT IN LOGGERHEAD TURTLES (CARETTA CARETTA)}, volume={52}, ISSN={["1937-2825"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85103729151&partnerID=MN8TOARS}, DOI={10.1638/2020-0159}, abstractNote={Abstract: Sea turtles are frequently presented for rehabilitation with injuries for which analgesic treatment is warranted. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) widely used in clinical veterinary medicine for musculoskeletal pain relief. Pharmacokinetics of 2 mg/kg IM have been studied in loggerhead sea turtles (Caretta caretta) as a single and a repeated dose q24hr for 3 days. Safety of longer term administration has not been performed, however, and NSAID use carries a risk of potential complications, including gastrointestinal ulceration, kidney damage, and bleeding. The objective of the current study was to determine the effects of a 5-day course of ketoprofen on thromboelastography (TEG) and hematological (including thrombocytes) and plasma biochemical analytes in loggerheads. A secondary objective was to determine 24-hr trough concentrations of ketoprofen after 5 days of treatment. Eight loggerheads were treated with ketoprofen 2 mg/kg IM q24hr for 5 days, and TEG, hematology, and plasma biochemistry panels were performed before and at the conclusion of treatment. Eight controls were treated with an equivalent volume of saline intramuscularly. Virtually no changes were detected before and after treatment or between treatment and control groups in any of the 24 endpoints evaluated, and marginal differences were not considered clinically relevant. Plasma ketoprofen concentrations after 5 days of treatment indicated no accumulation over that duration. Ketoprofen at 2 mg/kg IM q24hr for up to 5 days in loggerheads appears safe with respect to blood clotting and blood data, although other potential effects were not evaluated.}, number={1}, journal={JOURNAL OF ZOO AND WILDLIFE MEDICINE}, author={Harms, Craig A. and Ruterbories, Laura K. and Stacy, Nicole I and Christiansen, Emily F. and Papich, Mark G. and Lynch, Alex M. and Barratclough, Ashley and Serrano, Maria E.}, year={2021}, month={Mar}, pages={126–132} }
 @article{mariani_niman_boozer_ruterbories_early_munana_olby_2021, title={Vascular endothelial growth factor concentrations in the cerebrospinal fluid of dogs with neoplastic or inflammatory central nervous system disorders}, volume={6}, ISSN={["1939-1676"]}, url={https://doi.org/10.1111/jvim.16181}, DOI={10.1111/jvim.16181}, abstractNote={AbstractBackgroundVascular endothelial growth factor (VEGF) is a key molecular driver of angiogenesis and vascular permeability and is expressed by a wide variety of neoplasms. Although blood VEGF concentrations have been quantified in intracranial tumors of dogs, cerebrospinal fluid (CSF) VEGF concentration might be a more sensitive biomarker of disease.ObjectiveConcentrations of VEGF in CSF are higher in dogs with central nervous system (CNS) neoplasia compared to those with meningoencephalomyelitis and other neurologic disorders.AnimalsOne hundred and twenty‐six client‐owned dogs presented to a veterinary teaching hospital.MethodsCase‐control study. Cerebrospinal fluid was archived from dogs diagnosed with CNS neoplasia and meningoencephalomyelitis. Control dogs had other neurological disorders or diseases outside of the CNS. A commercially available kit was used to determine VEGF concentrations.ResultsDetectable CSF VEGF concentrations were present in 49/63 (77.8%) neoplastic samples, 22/24 (91.7%) inflammatory samples, and 8/39 (20.5%) control samples. The VEGF concentrations were significantly different between groups (P < .0001), and multiple comparison testing showed that both neoplastic and inflammatory groups had significantly higher concentrations than did controls (P < .05), but did not differ from each other. Gliomas and choroid plexus tumors had significantly higher VEGF concentrations than did the control group (P < .05).Conclusions and Clinical ImportanceCerebrospinal fluid VEGF concentrations may serve as a marker of neoplastic and inflammatory CNS disorders relative to other conditions.}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, publisher={Wiley}, author={Mariani, Christopher L. and Niman, Zachary E. and Boozer, Lindsay B. and Ruterbories, Laura K. and Early, Peter J. and Munana, Karen R. and Olby, Natasha J.}, year={2021}, month={Jun} }
 @article{lynch_ruterbories_griffith_hanel_stablein_brooks_2021, title={Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs}, volume={31}, ISSN={["1476-4431"]}, url={https://doi.org/10.1111/vec.13011}, DOI={10.1111/vec.13011}, abstractNote={AbstractObjectiveTo evaluate a panel of coagulation assays for their potential utility in rivaroxaban monitoring as alternatives to the rivaroxaban‐specific anti‐Xa activity (RIVA).DesignProspective experimental study.SettingUniversity research laboratory.AnimalsFive healthy neutered male Beagles.InterventionsDogs were administered a median dose of 1.8 mg/kg rivaroxaban (range, 1.6–1.8 mg/kg) orally once daily for 2 consecutive days as part of a pharmacodynamic study. Blood was collected from a preplaced jugular catheter at time points relative to their rivaroxaban administration (0, 2, 4, 8, 24, 36, and 48 h) for measurement of RIVA, prothrombin time (PT), activated partial thromboplastin time, RapidTEG, and thrombin generation variables.Measurements and main resultsOne hundred forty data points were available for analysis. There was poor correlation between RIVA and RapidTEG variables: R time (R) (min) (r = 0.554, P < 0.0001), K time (K) (min) (r = –0.204, P = 0.016), alpha angle (degrees) (r = 0.152, P = 0.073), Maximum amplitude (MA) (mm) (r = 0.106, P = 0.215), and G value (G) (dynes/s) (r = 0.108, P = 0.205). A good correlation was noted between thrombin generation variables and RIVA: lag time (min) (r = 0.827, P < 0.0001), peak (nM) (r = –0.752, P < 0.0001), and endogenous thrombin potential (nM·min) (r = –0.762, P < 0.0001). There was an excellent correlation between PT and RIVA (r = 0.915, P < 0.0001) and a good correlation between activated partial thromboplastin time and RIVA (r = 0.772, P < 0 .0001).ConclusionsOf all the coagulation tests investigated, the PT correlated best with RIVA. There is potential for PT being a convenient second‐line monitoring option in dogs receiving rivaroxaban, but further work is necessary to validate other PT assays. Thromboelastography performed with strong activators correlated poorly with anti‐Xa activity.}, number={1}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Lynch, Alex M. and Ruterbories, Laura K. and Griffith, Emily H. and Hanel, Rita M. and Stablein, Alyssa P. and Brooks, Marjory B.}, year={2021}, month={Jan}, pages={18–24} }
 @article{bomba_sheets_valdivia_khagi_ruterbories_mariani_borst_tokarz_hingtgen_2021, title={Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model}, volume={6}, ISSN={["2380-6761"]}, DOI={10.1002/btm2.10171}, abstractNote={AbstractIn this study, we take an important step toward clinical translation by generating the first canine‐induced neural stem cells (iNSCs). We explore key aspects of scale‐up, persistence, and safety of personalized iNSC therapy in autologous canine surgery models. iNSCs are a promising new approach to treat aggressive cancers of the brain, including the deadly glioblastoma. Created by direct transdifferentiation of fibroblasts, iNSCs are known to migrate through the brain, track down invasive cancer foci, and deliver anticancer payloads that significantly reduce tumor burden and extend survival of tumor‐bearing mice. Here, skin biopsies were collected from canines and converted into the first personalized canine iNSCs engineered to carry TNFα‐related apoptosis‐inducing ligand (TRAIL) and thymidine kinase (TK), as well as magnetic resonance imaging (MRI) contrast agents for in vivo tracking. Time‐lapse analysis showed canine iNSCs efficiently migrate to human tumor cells, and cell viability assays showed both TRAIL and TK monotherapy markedly reduced tumor growth. Using intraoperative navigation and two delivery methods to closely mimic human therapy, canines received autologous iNSCs either within postsurgical cavities in a biocompatible matrix or via a catheter placed in the lateral ventricle. Both strategies were well tolerated, and serial MRI showed hypointense regions at the implant sites that remained stable through 86 days postimplant. Serial fluid sample testing following iNSC delivery showed the bimodal personalized therapy was well tolerated, with no iNSC‐induced abnormal tissue pathology. Overall, this study lays an important foundation as this promising personalized cell therapy advances toward human patient testing.}, number={1}, journal={BIOENGINEERING & TRANSLATIONAL MEDICINE}, author={Bomba, Hunter N. and Sheets, Kevin T. and Valdivia, Alain and Khagi, Simon and Ruterbories, Laura and Mariani, Christopher L. and Borst, Luke B. and Tokarz, Debra A. and Hingtgen, Shawn D.}, year={2021}, month={Jan} }
 @article{lynch_ruterbories_griffith_hanel_stablein_brooks_2021, title={The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs}, volume={31}, ISSN={["1476-4431"]}, url={https://doi.org/10.1111/vec.13019}, DOI={10.1111/vec.13019}, abstractNote={AbstractObjectiveRivaroxaban is a new anticoagulant option for dogs, yet its reported oral bioavailability is as low as 60%. The objective of this study was to examine the influence of feeding and gastroprotectant medications on the bioactivity (anti‐Xa activity) of rivaroxaban in healthy dogs.DesignProspective experimental study.SettingUniversity research laboratory.AnimalsFive healthy neutered male purpose‐bred Beagles.InterventionsDogs were administered a median dose of 1.8 mg/kg rivaroxaban (range, 1.6‐1.8 mg/kg) orally once daily for 2 consecutive days with either (1) no food, (2) food, (3) sucralfate 30 minutes before rivaroxaban, or (4) omeprazole at the same time as rivaroxaban. Blood was collected from preplaced jugular catheters immediately before and at 6 time points after rivaroxaban administration (2, 4, 8, 24, 36, and 48 hours). A rivaroxaban calibrated anti‐Xa activity assay (RIVA) was used to monitor anticoagulant effect.Measurements and Main ResultsRivaroxaban administration resulted in significant increases in RIVA (P = 0.02), with peak activities occurring 2 to 4 hours after dosingduring each study arm. No feeding was associated with significantly higher RIVA at the 36‐hour time point compared to all other treatment arms (P < 0.0001), and feeding resulted in high RIVA at the 48‐hour time point compared with sucralfate administration (P = 0.003). No significant changes in RIVA were otherwise identified with respect to feeding or gastroprotectant administration (P = 0.2).Conclusions and Clinical ImportanceAlthough administration without food demonstrated an apparent increase in RIVA 36 hours after drug administration, clinically relevant differences among treatment groups were not identified in combined analyses of time points. Based on these results, dogs treated with rivaroxaban do not require special modification of feeding practices or gastroprotectant drug administration.}, number={1}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Lynch, Alex M. and Ruterbories, Laura K. and Griffith, Emily and Hanel, Rita M. and Stablein, Alyssa P. and Brooks, Marjory B.}, year={2021}, month={Jan}, pages={59–65} }
 @article{lynch_ruterbories_jack_motsinger-reif_hanel_2020, title={The influence of packed cell volume versus plasma proteins on thromboelastographic variables in canine blood}, volume={30}, ISSN={["1476-4431"]}, url={https://doi.org/10.1111/vec.12979}, DOI={10.1111/vec.12979}, abstractNote={AbstractObjectiveDetermine the correlation between kaolin‐activated thromboelastography (TEG) variables (R, K, angle, and maximum amplitude [MA]) and PCV, fibrinogen concentration (FC), and total fibrinogen (TF) in an ex vivo model.AnimalsTwo healthy adult mixed‐breed dogs.ProceduresCitrated whole blood was obtained and separated into packed red cells, platelet rich plasma, and platelet poor plasma (PPP). An aliquot of PPP was heated to denature heat labile proteins (fibrinogen, factor V, factor VIII). Blood components were recombined for analyses of 6 physiological scenarios: anemia with low fibrinogen; anemia with moderate fibrinogen; anemia with normal fibrinogen; anemia with normal saline; normal PCV and normal fibrinogen; and normal PCV and low fibrinogen. A Kruskal–Wallis test, along with linear regressions on pairwise combinations of TEG variables, was used to determine the correlation between TEG variables and PCV, FC, and TF.ResultsMaximum amplitude correlated with FC (R2 0.60, P < 0.001) and TF (R2 0.57, P < 0.001) but not PCV (R2 0.003, P = 0.7). Angle and K time were moderately correlated with FC ([angle: R2 0.53, P < 0.001]; [K: R2 0.55, P < 0.001]) and TF ([alpha angle: R2 0.52, P < 0.001]; [K: R2 0.51, P < 0.001]) but not PCV. The R time was weakly correlated with PCV (R2 0.15, P < 0.009) but not FC or TF.Conclusions and clinical relevanceIn an ex vivo model, plasma proteins but not PCV impacted TEG variables. This suggests that TEG changes noted with anemia are imparted by changes in available fibrinogen in a fixed microenvironment rather than artifact of anemia.}, number={4}, journal={JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE}, author={Lynch, Alex M. and Ruterbories, Laura and Jack, John and Motsinger-Reif, Alison A. and Hanel, Rita}, year={2020}, month={Jul}, pages={418–425} }
 @article{barratclough_tuxbury_hanel_stacy_ruterbories_christiansen_harms_2019, title={Baseline plasma thromboelastography in Kemp’s ridley (Lepidochelys kempii), green (Chelonia mydas) and loggerhead (Caretta caretta) sea turtles and its use to diagnose coagulopathies in cold-stunned Kemp’s ridley and green sea turtles}, volume={50}, ISSN={1042-7260}, url={http://dx.doi.org/10.1638/2018-0142}, DOI={10.1638/2018-0142}, abstractNote={Abstract 
 Cold-stunning in sea turtles is a frequent natural cause of mortality and is defined as a hypothermic state due to exposure to water temperatures <12°C. Derangements of biochemistry and hematology data by cold stunning have been well documented, although the effects on coagulation have not yet been investigated. The objectives of this study were to characterize the hemostatic state of non–cold-stunned sea turtles and to compare cold-stunned sea turtles at admission and after successful rehabilitation via a sea turtle–specific thromboelastography (TEG) protocol. TEG enables evaluation of the entire coagulation process, and the methodology has recently been established in sea turtles. Initially, 30 wild and apparently healthy sea turtles were sampled as controls: loggerhead sea turtles (Caretta caretta), n =17; Kemp's ridley sea turtles (Lepidochelys kempii), n = 8; and green turtles (Chelonia mydas), n = 5. In addition, paired TEG samples were performed on 32 Ch. mydas and 14 L. kempii at admission and prerelease after successful rehabilitation from cold stunning. Statistically significant differences in reaction time, kinetics, angle, and maximum amplitude parameters in L. kempii and Ch. mydas species demonstrated that the time taken for blood clot formation was prolonged and the strength of the clot formed was reduced by cold stunning. These findings indicate that cold stunning may cause disorders in hemostasis that can contribute to the severity of the condition. Early diagnosis of coagulopathies in the clinical assessment of a cold-stunned sea turtle may influence the treatment approach and clinical outcome of the case.}, number={1}, journal={Journal of Zoo and Wildlife Medicine}, publisher={American Association of Zoo Veterinarians}, author={Barratclough, A. and Tuxbury, K. and Hanel, R. and Stacy, N.I. and Ruterbories, L. and Christiansen, E. and Harms, C.A.}, year={2019}, month={Apr}, pages={62} }
 @article{tang_su_huang_dinh_wang_vandergriff_hensley_cores_allen_li_et al._2018, title={Targeted repair of heart injury by stem cells fused with platelet nanovesicles}, volume={2}, ISSN={2157-846X}, url={http://dx.doi.org/10.1038/s41551-017-0182-x}, DOI={10.1038/s41551-017-0182-x}, abstractNote={Stem cell transplantation, as used clinically, suffers from low retention and engraftment of the transplanted cells. Inspired by the ability of platelets to recruit stem cells to sites of injury on blood vessels, we hypothesized that platelets might enhance the vascular delivery of cardiac stem cells (CSCs) to sites of myocardial infarction injury. Here, we show that CSCs with platelet nanovesicles fused onto their surface membranes express platelet surface markers that are associated with platelet adhesion to injury sites. We also find that the modified CSCs selectively bind collagen-coated surfaces and endothelium-denuded rat aortas, and that in rat and porcine models of acute myocardial infarction the modified CSCs increase retention in the heart and reduce infarct size. Platelet-nanovesicle-fused CSCs thus possess the natural targeting and repairing ability of their parental cell types. This stem cell manipulation approach is fast, straightforward and safe, does not require genetic alteration of the cells, and should be generalizable to multiple cell types.}, number={1}, journal={Nature Biomedical Engineering}, publisher={Springer Science and Business Media LLC}, author={Tang, Junnan and Su, Teng and Huang, Ke and Dinh, Phuong-Uyen and Wang, Zegen and Vandergriff, Adam and Hensley, Michael T. and Cores, Jhon and Allen, Tyler and Li, Taosheng and et al.}, year={2018}, month={Jan}, pages={17–26} }